{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibs6vwwxnskenlo66u3sbtntkux6xdtkrpcep6z44s2scboxub4ee",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mntmzur75t32"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreicpdxxygxw3l2bsyvnfarjodsgujz6vp55pm5a6joetw2n3kcs3yi"
    },
    "mimeType": "image/jpeg",
    "size": 145660
  },
  "path": "/2026/06/09/gsk-nuvalent-acquistion-oncology-lung-cancer-zidesamtinib-neladalkib/?utm_campaign=rss",
  "publishedAt": "2026-06-09T06:48:20.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Pharma",
    "Cancer",
    "drug development",
    "Pharmaceuticals",
    "STAT+"
  ],
  "textContent": "GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.",
  "title": "STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B",
  "updatedAt": "2026-06-09T06:48:24.000Z"
}